AIDS and Behavior

, Volume 22, Issue 4, pp 1217–1227 | Cite as

Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China

  • Kathrine Meyers
  • Yumeng Wu
  • Haoyu Qian
  • Theodorus Sandfort
  • Xiaojie Huang
  • Junjie Xu
  • Jing Zhang
  • Wei Xia
  • David Glidden
  • Hao Wu
  • Hong Shang
Original Paper


Long-acting injectable (LAI) formulations of antiretrovirals (ARVs) as pre-exposure prophylaxis (PrEP) could be an attractive alternative for men who have sex with men (MSM) who are interested in ARV-based biomedical prevention but will not use a daily pill. This study investigated interest in LAI-PrEP in a cohort of MSM in China and characterized how MSM willing to use only injectable PrEP differed from MSM who would use PrEP regardless of modality or not at all. Demographic, behavioral, and risk perception measures were collected and associations investigated. A licensed LAI-PrEP agent would increase the proportion interested in PrEP by 24.5% over oral PrEP alone. Combining interest in oral and injectable PrEP, 78.5% of the sample could be covered if reported interest in PrEP translated into actual uptake. Partnership factors differentiated those who would be willing to use only LAI-PrEP versus any PrEP modality, while higher self-perception of risk was associated with interest in LAI-PrEP versus no PrEP. The addition of a second PrEP modality could yield increased population coverage of PrEP. Social and behavioral research should be undertaken in parallel with clinical development of injectable PrEP agents to identify characteristics of those who are not interested in oral PrEP but would take advantage of ARV-based prevention with the introduction of an injectable product.


HIV Biomedical HIV prevention PrEP China Men who have sex with men Long-acting injectable PrEP 



Contributions from Dr. Meyers, Ms. Wu, Mr. Qian, were supported by the China AIDS Initiative under the leadership of Dr. David Ho. Dr. Meyers was also supported by Grant # UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. Dr. Sandfort’s contribution was supported by NIMH center Grant P30-MH43520 (P.I.: Robert Remien, PhD) to HIV Center for Clinical and Behavioral Research. The contribution of Drs. Shang, Xu, and Zhang were supported by the Mega-Projects of National Science Research for the 12th Five-Year Plan (2012ZX10001-006); they thank Dr. Yongjun Jiang for support. Dr. Glidden’s contributions were supported by Grant #s R03 AI120819 and R03 AI122908.

Compliance with Ethical Standards

Conflict of interest

The authors declares that they have no conflict of interest.

Supplementary material

10461_2017_1845_MOESM1_ESM.xlsx (20 kb)
Supplementary material 1 (XLSX 20 kb)


  1. 1.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Marcus JL, Volk JE, Pinder J, Liu AY, Bacon O, Hare CB, et al. Successful implementation of HIV preexposure prophylaxis: lessons learned from three clinical settings. Curr HIV/AIDS Rep. 2016;13(2):116–24.CrossRefPubMedGoogle Scholar
  4. 4.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMedGoogle Scholar
  6. 6.
    World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV 2015.Google Scholar
  7. 7.
    Xu JJ, Tang WM, Zou HC, Mahapatra T, Hu QH, Fu GF, et al. High HIV incidence epidemic among men who have sex with men in china: results from a multi-site cross-sectional study. Infect Dis Poverty. 2016;5(1):82.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jia Z, Huang X, Wu H, Zhang T, Li N, Ding P, et al. HIV burden in men who have sex with men: a prospective cohort study 2007–2012. Sci Rep. 2015;5:11205.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Peng B, Yang X, Zhang Y, Dai J, Liang H, Zou Y, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV AIDS. 2012;4:149–58.Google Scholar
  10. 10.
    Ye L, Wei S, Zou Y, Yang X, Abdullah AS, Zhong X, et al. HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China. PLoS ONE. 2014;9(1):e86200.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mijiti P, Yahepu D, Zhong X, Sun Y, Zhao T, Zhao Z, et al. Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention among HIV-serodiscordant heterosexual couples: a cross-sectional survey in Xinjiang, China. PLoS ONE. 2013;8(7):e67392.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y. Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav. 2012;16(7):1853–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Xue H, Liu H, Cai L. Analysis of willingness and influencing factors for usage of pre-exposure prophylaxis among men who have sex with men. Chin J Prev Med. 2015;49(11):973–7.Google Scholar
  14. 14.
    Zhang Y, Peng B, She Y, Liang H, Peng H-B, Qian H-Z, et al. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDS. 2013;27(3):137–41.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS ONE. 2012;7(3):e32329.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ding Y, Yan H, Ning Z, Cai X, Yang Y, Pan R, et al. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China. Biosci Trends. 2016;10(2):113–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Meyers K, Wu Y, Golub S. To switch or not to switch: anticipating choices in biomedical HIV prevention. Poster session presented at: HIV Research for Prevention Conference; October 17–21; Chicago. 2016.Google Scholar
  18. 18.
    Xu J-J, Zhang M, Brown K, Reilly K, Wang H, Hu Q, et al. Syphilis and HIV seroconversion among a 12-month prospective cohort of men who have sex with men in Shenyang, China. Sex Transm Dis. 2010;37(7):432–9.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, et al. Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016;13(5):465–73.Google Scholar
  20. 20.
    Greene GJ, Swann G, Fought AJ, Carballo-Dieguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2017;21(5):1336–49.CrossRefPubMedGoogle Scholar
  21. 21.
    Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wheelock A, Eisingerich AB, Ananworanich J, Gomez GB, Hallett TB, Dybul MR, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE. 2013;8(1):e54288.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chow EP, Wilson DP, Zhang L. What is the potential for bisexual men in China to act as a bridge of HIV transmission to the female population? Behavioural evidence from a systematic review and meta-analysis. BMC Infect Dis. 2011;11(1):242.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Merchant RC, Corner D, Garza E, Guan W, Mayer KH, Brown L, et al. Preferences for HIV pre-exposure prophylaxis (PrEP) information among men-who-have-sex-with-men (MSM) at community outreach settings. J Gay Lesbian Ment Health. 2016;20(1):21–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Mimiaga MJ, Closson EF, Battle S, Herbst JH, Denson D, Pitts N, et al. Reactions and receptivity to framing HIV prevention message concepts about pre-exposure prophylaxis for Black and Latino men who have sex with men in three urban US cities. AIDS Patient Care STDS. 2016;30(10):484–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Underhill K, Morrow KM, Colleran C, Calabrese SK, Operario D, Salovey P, et al. Explaining the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention: a qualitative study of message framing and messaging preferences among US men who have sex with men. AIDS Behav. 2016;20(7):1514–26.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gamarel KE, Golub SA. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2015;49(2):177–86.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Golub SA. Tensions between the epidemiology and psychology of HIV risk: implications for pre-exposure prophylaxis. AIDS Behav. 2014;18(9):1686–93.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Kathrine Meyers
    • 1
    • 6
  • Yumeng Wu
    • 1
  • Haoyu Qian
    • 1
  • Theodorus Sandfort
    • 2
  • Xiaojie Huang
    • 3
  • Junjie Xu
    • 4
  • Jing Zhang
    • 4
  • Wei Xia
    • 3
  • David Glidden
    • 5
  • Hao Wu
    • 3
  • Hong Shang
    • 4
  1. 1.Aaron Diamond AIDS Research CenterThe Rockefeller UniversityNew YorkUSA
  2. 2.HIV Center for Clinical and Behavioral StudiesColumbia UniversityNew YorkUSA
  3. 3.Center for Infectious Diseases, Beijing You’an HospitalCapital Medical UniversityBeijingChina
  4. 4.Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated HospitalChina Medical UniversityShenyangChina
  5. 5.University of CaliforniaSan FranciscoUSA
  6. 6.Aaron Diamond AIDS Research CenterNew YorkUSA

Personalised recommendations